Imupharm Immune Health Onco Nutrition Heart Health Endocrine Health Joint and Bone Health Digestive Support Men's Health Women's Health Detox Support

Advanced Integrative Immunotherapy for Cancer





Imupharm Probiotic

SUGGESTED USE: 1 capsule per day or as recommended by your health care professional.

Formulated to be free of allergens derived from: Gluten, corn, artificial colors and flavors. If you are pregnant or nursing, consult your physician before taking this product. As with all dietary supplements, some individuals may not tolerate or may be allergic to the ingredients used. Please read the ingredient panel carefully prior to ingestion. Cease taking this product and consult your physician if you have negative reactions upon ingestion.

Contraindications, Adverse or Other Reactions: Probiotics are considered very safe with no known adverse affects. Some changes in the stool may be noted and occasionally some people notice a temporary increase in digestive gas.

DISCLAIMER: The information contained on this web site has not been evaluated by the FDA. It is not intended to treat, diagnose, cure or prevent any disease. Material on the Imupharm web site is provided for educational purposes only. Always seek the advice of your physician or other qualified health care provider with any questions you have regarding a medical condition, and before undertaking any diet, exercise or other health program.

Over 300 different strains of bacteria compete for the environment within the lower gastrointestinal tract. Strains that promote health (probiotic), as well as those that cause disturbances compete for space and nutrients.

When there is a healthy balance (eubiosis), few symptoms exist. On the other hand, dysbiosis occurs when fewer than normal probiotic organisms and an over abundance of potentially harmful bacteria, yeast or parasitic organisms prevail. Dysbiosis often results in a number of gastrointestinal symptoms.

    Events that often trigger dysbiosis include:
    • Antibiotic use
    • Foods contaminated with parasites and bacteria
    • Abdominal irradiation
    • Use of NSAIDs and other drugs
    • Foods that lead to gut inflammation

    • Indirect (passive) activity due to competition for attachment sites and nutrients, against strains such as E. coli, Salmonella, and Yersinia (References 1,2,3).
    • Alters pH environment.
    • Active secretion of anti-microbial and anti-yeast components that inhibit non-beneficial organisms.
    • Increased mucosal immunity (References 4,5)
    • Increased immune cell phagocytosis (Reference 6)
    • Increased NK cell activity after ingesting L. rhamnosus (Reference 7)
    • Protection from carcinogens (References 8,9,10)
    • Potential cholesterol lowering activity (Reference 11)
    • Increased production of Short-Chained Fatty Acids for energy along gut mucosa (Reference 12)


Probiotic Strains

Lactobacillus acidophilus (Reference 13):
    • Protects human epithelial cells from invasion of E. coli.
    • Decreases bacterial enzymes implicated in colon carcinogenesis.
    • L. acidophilus, fed by means of a fermented milk product, was shown to increase phagocytic and lymphocytic activity in mice.

Lactobacillus paracasei:
    • L. acidophilus in combination with L. paracasei reduce diarrheal duration and vomiting in children (6-24 months) suffering from persistent diarrhea (Reference 13).

Bifidobacterium bifidum (Reference 14):
    • B. bifidum has a high tolerance against stomach acids.
    • B. bifidum can effectively inhibit E. coli and Staphylococcus aureus.

Bifidobacterium lactis (Reference 15):
    • In an in vitro study, Bifidobacterium strains were able to inhibit gastrointestinal pathogen adhesion on and/or invasion in human intestinal cells.
    • Studies show that B. lactis may help prevent allergies in infants.

Lactobacillus plantarum (Reference 16):
    • L. plantarum has a protective effect by down regulating IL-8 secretion (a pro-inflammatory cytokine).
    • A double-blind placebo controlled study containing 60 people with IBS, showed L. plantarum reduced flatulence and maintained a better overall GI function than in the placebo group.

Lactobacillus rhamnosus :
    • Increased NK cell activity after ingesting L. rhamnosus (Reference 7).
    • Used in the prevention and treatment of diarrhea, primarily in children (Reference 20).
    • Specific strains of Lactobacillus rhamnosus have been found to inhibit the adhesion of Salmonella to Caco-2 cells via a pH effect (Reference 20).

Saccharomyces boulardii:
    • S. boulardii is a brewers yeast. It has been approved in Germany for the treatment of chronic acne, boils, acute and traveler’s diarrhea (Reference 17).
    • 200 children with acute diarrhea were randomly given 250 mg/day S. boulardii or placebo. Stool frequency, duration of diarrhea, and hospital stay were all greatly improved in the group that received the S. boulardii (Reference 18).
    • S. boulardii stimulates PPAR-gamma expression and reduces response of human colon cells to pro-inflammatory cytokines (Reference 19).

Product Viability:           
In order to maximize strain viability at room temperature the following manufacturing parameters are followed:
    • The organisms are produced under a unique process called FloraFit to maximize room temperature stability.
    • Strains are frozen under nitrogen before shipment to the laboratory.
    • After thawing, product is encapsulated and bottled in one production cycle to minimize exposure to moisture and air.
    • Product is packed with desiccant to prevent moisture damage to product.

Colony Forming Units:
At the time of manufacture, there are approximately 30-42 billion Colony Forming Units per capsule, in order to ensure the presence of 20 billion CFU’s at the time of expiration (1 year after manufacturing).

(1) Bernet MF, Brassart D, Neeser JR, Servin AL. Adhesion of human bifidobacterial strains to cultured human intestinal epithelial cells and inhibition of enteropathogen-cell interactions. Appl Environ Microbiol 1993; 59(12):4121-8.

(2) Bernet MF, Brassart D, Neeser JR, Servin AL. Lactobacillus acidophilus LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. Gut 1994; 35(4):483-9.

(3) Coconnier MH, Bernet MF, Kerneis S, et al. Inhibition of adhesion of enteroinvasive pathogens to human intestinal Caco-2 cells by Lactobacillus acidophilus strain LB decreases bacterial invasion. FEMS Micorbial Lett 1993; 110(3):299-305.

(4) Majamaa H, Isolauri E, Saxelin M, Vesikari T. Lactic acid bacteria in the treatment of acute rotavirus gastroenteritis. J Pediatr Gastroenterol Nutr 1995; 20(3):333-8.

(5) De Simone C, Ciardi A, Grassi A, et al. Effect of Bifidobacterium bifidum and Lactobacillus acidophilus on gut mucosa and peripheral blood B lymphocytes. Immunopharmacol Immunotoxicol 1992; 14(1-2):331-40.

(6) Schiffrin EJ, Brassart D, Servin AL, et al. Immune modulation of blood leukocytes in humans by lactic acid bacteria: criteria for strain selection. Am J Clin Nutr 1997; 66(2):515S-520S.

(7) Sheih YH, Chiang BL, Wang LH, Liao CK, Gill HS Systemic immunity-enhancing effects in healthy subjects following dietary consumption of the lactic acid bacterium Lactobacillus rhamnosus HN001 J Am Coll Nutr 2001; 20(2 Suppl):149-56.

(8) Hayatsu H, Hayatsu T. Suppressing effect of Lactobacillus casei administration on the urinary mutagenicity arising from ingestion of fried ground beef in the human. Cancer Lett 1993; 73(2-3):173-9.

(9) Orrhage K, Sillerstrom E, Gustafsson JA, et al. Binding of mutagenic heterocyclic amines by intestinal and lactic acid bacteria. Mutat Res 1994; 311(2):239-48.

(10) Reddy BS, Rivenson A. Inhibitory effect of Bifidobacterium longum on colon, mammary, and liver carcinogenesis induced by 2-amino-3-methylimidazo[4,5-f]quinoline, a food mutagen. Cancer Res 1993; 53(17):3914-8.

(11) Klaver FA, van der Meer R. The assumed assimilation of cholesterol by Lactobacilli and Bifidobacterium bifidum is due to their bile salt-conjugating activity. Appl Environ Microbiol 1993; 59(4):1120-4.

(12) Holzapfel WH, Haberer P, Snel J. et al. Overview of gut flora and probiotics. Int J Food Microbiol 1998; 41:85-101.

(13) Danisco. Lactobacillus acidophilus La-14 probiotic identity card.

(14) Danisco. Bifidobacterium bifidum Bb-02 technical information.

(15) Danisco. Bifidobacterium lactis BI-04 probiotic identity card.

(16) Danisco. Lactobacillus plantarum Lp-115 probiotic identity card.

(17) American Botanical Council. Yeast, Brewer’s/Hansen CBS 5926. []

(18) Kurugol Z, Koturoglu G. Effects of Saccharomyces bouldardii in children with acute diarrhea. Acta Paediatr. 2005; 94(1):44-47.

(19) Lee SK, et al. Saccharomyces boulardii activates expression of peroxisome proliferators-activated receptor-gamma in HT-29 cells. Korean J Gastroenterol. 2005; 45(5):328-334.

(20) Guilliams, T. Healthy Microbial Organisms HMOs You Can Really Count On. The Standard. 1999; 2(2).